Salarius Pharmaceuticals Inc (NASDAQ:SLRX)’s traded shares stood at 2.29 million during the last session, with the company’s beta value hitting 0.59. At the close of trading, the stock’s price was $1.45, to imply an increase of 29.46% or $0.33 in intraday trading. The SLRX share’s 52-week high remains $7.20, putting it -396.55% down since that peak but still an impressive 26.9% since price per share fell to its 52-week low of $1.06.

Salarius Pharmaceuticals Inc (NASDAQ:SLRX) trade information

After registering a 29.46% upside in the last session, Salarius Pharmaceuticals Inc (SLRX) has traded red over the past five days. The 5-day price performance for the stock is 2.11%, and -41.06% over 30 days. With these gigs, the year-to-date price performance is -21.20%.

SLRX Dividends

Salarius Pharmaceuticals Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Salarius Pharmaceuticals Inc (NASDAQ:SLRX)’s Major holders

We also have Fidelity Extended Market Index Fund and Listed Funds Tr-Horizon Kinetics Medical ETF as the top two Mutual Funds with the largest holdings of the Salarius Pharmaceuticals Inc (SLRX) shares. Going by data provided on Dec 31, 2024, Fidelity Extended Market Index Fund holds roughly 5.74 shares. This is just over 0.36% of the total shares, with a market valuation of $8320.0. Data from the same date shows that the other fund manager holds a little less at 3.72, or 0.24% of the shares, all valued at about 5398.0.